Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug Demonstrates Poor Efficacy in Advanced Bladder Cancer
Clinical Breakthroughs

Drug Demonstrates Poor Efficacy in Advanced Bladder Cancer

By Melissa RohmanApr 29, 2021
Share
Facebook Twitter Email
Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, was a study steering committee member and co-author of the clinical trial published in The Lancet Oncology.

An FDA-approved monoclonal antibody drug used to treat advanced bladder cancer demonstrated poor efficacy in a recent clinical trial published in The Lancet Oncology.

Muscle invasive urothelial carcinoma (MIUC), the most common type of bladder cancer, is characterized by cancerous urothelial cells that line the inside of the bladder and urinary tract wall. The cancer is aggressive and can spread despite the use of available treatments.

The current standard of care for patients with MIUC is a combination of surgery and cisplatin-based neoadjuvant chemotherapy. However, almost half of patients are ineligible for this treatment due to inherent frailty, comorbidities or impaired kidney function. Coupled with the cancer’s high recurrence rate, developing novel therapies for this patient population continues to remain high priority.

“Despite progress to date, MIUC continues be a high-risk disease despite curative intent therapy. It’s therefore very critical to continue to investigate new agents and combination therapy to further enhance the chance for a cure,” said Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, and a study steering committee member and co-author of the clinical trial.

For the current clinical trial, Hussain and collaborators evaluated the efficacy of atezolizumab, a monoclonal antibody cancer drug approved by the Food and Drug Administration, in treating patients with advanced MIUC.

“The safety profile for atezolizumab was consistent with that observed in prior studies in the advanced setting, with no new safety concerns,” said Hussain, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Investigators enrolled 800 adult patients with MIUC from 24 different countries who had surgery, either a radical cystectomy or a nephroureterectomy with lymph node dissection.

Patients were then randomized to receive 1,200 milligrams of atezolizumab intravenously every three weeks for one year or be kept under observation without additional treatment after surgery.

Overall, the atezolizumab group did not show significant improvement in disease-free survival compared to the observation group — average disease-free survival was 19.4 months for the atezolizumab group compared to 16.6 months for the observation group.

Additionally, serious adverse events occurred in 31 percent of patients who received atezolizumab compared to 18 percent of patients in the observation group.

“Atezolizumab was generally tolerable, with no new safety signals; however, higher frequencies of adverse events leading to discontinuation were reported than in metastatic urothelial carcinoma studies. These data do not support the use of atezolizumab in the setting evaluated in IMvigor010 at this time,” the authors wrote.

This work was supported by F Hoffmann-La Roche/Genentech.

Cancer Medicine Research
Share. Facebook Twitter Email

Related Posts

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023

Comments are closed.

Latest News

Medical Education Day Celebrates Mentorship and Equity

Sep 29, 2023

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Lloyd-Jones Announces He is Stepping Down as Chair of Preventive Medicine

Sep 27, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230927_MedEdDay_Sargent_6
20230927_MedEdDay_Sargent_3
20230927_MedEdDay_Sargent_1
20230927_MedEdDay_Posters_Patel_2
20230927_MedEdDay_Posters_Patel_1
20230927_MedEdDay_Posters_Panko_1
20230927_MedEdDay_Posters_4
20230927_MedEdDay_Posters_3
20230927_MedEdDay_Posters_2
20230927_MedEdDay_Posters_1
20230927_MedEdDay_Awards_6
20230927_MedEdDay_Awards_5

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.